RADICAVA
PeakNDAINTRAVENOUSSOLUTION
Approved
May 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 13h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RADICAVA (edaravone) is a small-molecule intravenous infusion approved for amyotrophic lateral sclerosis (ALS), a rapidly progressive neurodegenerative disease. The exact mechanism of action remains unknown, though edaravone demonstrates dose-proportional pharmacokinetics with a half-life of 4.5–9 hours. An oral formulation (RADICAVA ORS) was subsequently approved, offering patients an alternative to IV administration.
$0.011BPart D
PeakDrug is at peak lifecycle stage with modest Medicare utilization (868 Part D claims in 2023), indicating a stable but niche commercial footprint for a specialized neurology indication.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
Started Oct 2019
74 enrolled
Amyotrophic Lateral SclerosisALS
Career Relevance
RADICAVA's peak lifecycle stage and niche ALS market indicate a stable but small commercial team focused on maintaining market share and managing payer relationships rather than driving growth. Career opportunities are limited in scale but offer deep specialization in neurology and rare disease management.
Brand Manager
Worked on RADICAVA at Tanabe Pharma America? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.